Study of Patients With Thrombotic Microangiopathy Associated With

Status Recruiting

Clinical Trial Summary

Thrombotic microangiopathies (TMA) are defined as a triad combining mechanical hemolytic anemia, peripheral thrombocytopenia and ischemic organ damage. Mitomycin C is an alkylating agent used as chemotherapy in adenocarcinomas of the breast, lung, pancreas, rectum and anal carcinoma. Mitomycin-C-induced TMA (m-TMA) is a potentially serious complication of chemotherapy: its estimated incidence ranges from 4 to 15% and its mortality exceeds 70%, with an estimated median survival of 2 months. This can also be responsible for kidney failure, sometimes requiring hemodialysis. The time to onset of m-TMA varies from one week to 15 months after the last infusion and is believed to depend on the cumulative dose of mitomycin C. Eculizumab is a monoclonal antibody that binds to complement protein C5, blocking activation of the terminal complement pathway and formation of the membrane attack complex. This therapy has significantly changed the prognosis of patients with atypical hemolytic uremic syndrome (HUS), a disease in which complement activation plays a central role in TMA. Recently, a retrospective study suggested efficacy of eculizumab in TMA induced by gemcitabine, another chemotherapy, with normalization of platelets and LDH in 83% of patients, and partial or complete renal recovery in 67% and 17% of patients. These results provided arguments in favor of a potential benefit of complement-targeted therapies in TMA induced by certain chemotherapies. However, data on eculizumab in m-TMA remain extremely limited to date. The objective of this study is to describe the clinical, biological and histological presentation of patients with m-TMA and their evolution after treatment with or without eculizumab.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06098378
Study type	Observational
Source	University Hospital, Strasbourg, France
Contact	Anna DUVAL, MD
Phone	33 3 69 55 05 11
Email	anna.duval@chru-strasbourg.fr
Status	Recruiting
Phase
Start date	June 7, 2023
Completion date	June 7, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04098445` - TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
Recruiting	`NCT03605511` - TTP and aHUS in Complicated Pregnancies
Not yet recruiting	`NCT05996679` - Automated Surveillance, Alert, and Rapid Diagnosis of Thrombotic Microangiopathies: the ASARD-TMA Study
Completed	`NCT02222545` - Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies	Phase 2
Recruiting	`NCT06102694` - Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
Completed	`NCT03252925` - A Safety and Efficacy Study of NAC in Patients With TA-TMA	Phase 3
Recruiting	`NCT05855083` - Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA	Phase 2
Completed	`NCT03384693` - Defibrotide TMA Prophylaxis Pilot Trial	Phase 2
Not yet recruiting	`NCT05702996` - Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies	Phase 3
Not yet recruiting	`NCT02373267` - Screening of TMA Patients für ADAMTS13 Activity (Adamscreen)	N/A
Completed	`NCT02134171` - Early Predictive Factors of Cardiac and Cerebral Involvement in TMA	N/A
Not yet recruiting	`NCT06182410` - Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma	Phase 2
Withdrawn	`NCT04970004` - Study in Adult and Pediatric Patients With HSCT-TMA
Recruiting	`NCT03205995` - Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome	Phase 3
Recruiting	`NCT04784455` - Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy	Phase 3
Active, not recruiting	`NCT04570397` - Ravulizumab and COVID-19	Phase 3
Recruiting	`NCT05634928` - Construction of a Database for TMA
Completed	`NCT03518203` - Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients	Phase 2
Recruiting	`NCT04745195` - Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
Recruiting	`NCT06291415` - The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab — m-TMA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms